Q Biomed Announces Licensing Agreement for Development of Drug to Treat Rare Pediatric Disorder New Treatment in Development Looks to Treat Rare Condition that Robs Approximately 20,000 US Children per Year of their Ability to Speak

NEW YORK, April 25, 2017 Q BioMed Inc. (OTCQB: QBIO) and ASDERA LLC today announce a licensing agreement that provides Q Biomed with the worldwide exclusive rights to ASDERA's ASD-002, which is being developed to treat a rare pediatric nonverbal disorder. Under...